PCI Biotech Reports Successful Completion of Second Dose Group in Pivotal Amphinex(R) Trial
Published: Jan 19, 2010
OSLO--(BUSINESS WIRE)--PCI Biotech AS ( PCIB.OL) (OSE:PCIB) reported today that it has completed the successful treatment of the second dose group in the phase I/II study of its proprietary photosensitiser Amphinex® used in combination with the cytotoxic agent bleomycin in cancer patients. To date seven patients have been given a single photochemical internalisation (PCI) treatment of Amphinex® with all the treated tumours in all patients disappearing within a few weeks of treatment. Furthermore, no drug-related serious adverse events have been recorded.